Drug Repositioning: Successful Strategies to Extend the Product Life Cycle Four Case Studies

Held Aug. 25, 2008

While drug approvals are decreasing and blockbuster products face generic competition, pharma companies are increasingly turning to drug repositioning as a way to glean more profits from products either off patent or about to go off patent.

In addition to the more commonly used drug repositioning strategies, drugmakers are seeking approval for additional patient populations or by changing the formulation from an immediate-release drug to extended release.

But consider this …

In the wake of last year’s Supreme Court ruling in KSR Int’l. v. Teleflex, which expanded the “obviousness” test, it’s more difficult to get patent protection for products that are similar to the original. Any company that attempts to develop a repositioning plan without a focus on patentability could result in disaster.

How can you determine which strategy offers the best chance for a high-dollar return — new formulation or new indications? Which is riskier? Should the repositioning be done in-house or should it be outsourced to a specialty firm?

Here’s how …

Patent attorney Richard B. Smith will tell you how to put together an effective plan for repositioning your products, including case studies of successes and failures, the benefits and risks of outsourcing, and ways to ensure patent protection.

Order today to listen in and discover:

  • Different types of drug repositioning and their benefits
  • What market forces are driving the increase in drug repositioning
  • Examples of repositioning efforts that succeeded and those that failed (and why) in four case studies
  • The eight key elements of a successful repositioning strategy
  • Challenges and considerations for intellectual property protection, and the possible effects of the KSR v. Teleflex opinion
  • Six potential pitfalls — what can go wrong
  • How to pick a repositioning partner

Don’t give generic competition the opportunity to get its new drug on the market!

This audio CD/Transcript is a must for and professionals in both drug and biologic industries, including:
  • Sales and marketing
  • General and corporate counsel
  • Regulatory and legislative affairs
  • Compliance officers
  • Executive management
  • Quality management
  • Business development
  • Manufacturing directors and supervisors
  • Patent attorneys

Phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Richard B. Smith is a partner with the law firm Edwards Angell Palmer & Dodge and co-chair of the firm's Life Sciences practice group. He concentrates his practice on strategic business collaborations for biotechnology and biomedical device companies typically involving licensing, marketing, supply and co-promotion transactions. Richard also advises on corporate issues common to technology companies, including venture capital financing, mergers and acquisitions, and all business aspects of intellectual property law. He is a registered patent attorney whose practice includes obtaining and enforcing patent, copyright, trademark and trade secret protection. 

After graduating from the Rensselaer Polytechnic Institute with an undergraduate degree in Biomedical Engineering and a master's degree in Electrical Engineering, Richard worked as an engineer for the Hewlett-Packard Company for nine years and was primarily involved with the design and manufacturing of cardiac ultrasound imaging equipment. He holds three patents related to his work at Hewlett-Packard.

Order now!